The animal health industry is perplexed over FDA's unexpected withdrawal of its guidance on professional flexible labeling of antimicrobial drugs.








The Honorable Thomas A. Scully


Centers for Medicare and Medicaid Services

200 Independence Avenue SW

Washington, D.C. 20201

Dear Mr. Scully;

We appreciate your willingness to meet with Families USA, the Center on Budget and Policy Priorities and the National Health Law Program on Monday to discuss the Medicaid waiver process and its potential impact on current Medicaid beneficiaries. In preparation for that meeting, I would like to share with you some of the concerns we hope to raise at the meeting.



Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.